Biopharmx Corp (NYSEAMERICAN:BPMX) To Showcase BPX-04 Rosacea Data


Biopharmx Corp (NYSEAMERICAN:BPMX) will showcase to the medical community preliminary report from the cure of rosacea utilizing its novel topical gel named BPX-04. BPX-04 marks as the firm’s latest addition to its clinical product pipeline.

The details

Biopharmx reported that BPX-04 marks as the second product advanced on the patent-pending company’s hydrophilic topical delivery system. The drug reinforces the value of the innovative delivery mechanism as company researchers evaluate other applications. As per the latest update, BioPharmX presentations will comprise a presentation on cutaneous Tolerability of a unique topical Minocycline Gel targeting Rosacea. This presentation will be done Maui Derm for Dermatologists 2018 event, January 28 – February 1. The poster will exhibit that most patients’ ratings for stinging, tightness, itching and burning were unchanged or improved.

Earlier, the company gave a presentation at the Winter Clinical Dermatology Conference that was held from January 12 to January 17 in Hawaii. The poster showcased that BPX-04 reported clinically meaningful improvements after just 4-weeks of treatment.

Anja Krammer, the President and Co-founder of Biopharmx, expressed that the promise of BPX-04 sustains to reinforce the value of their topical delivery system and its feature to offer new therapies for several indications. These presentations allow them to fulfill the demand for data on their research and communicate outcome of promising topical treatments to physicians.

Moreover, Biopharmx will be showcased in discussions of developing therapies, featuring BPX-04 for rosacea and BPX-01 for acne. The company has successfully concluded a Phase 2b study for BPX-01 and is getting set for Phase III studies. It is currently performing a pilot clinical trial for BPX-04 and is looking forward for a Phase 2 study.

BPX-041 and BPX-011 are hydrophilic topical gels having fully solubilized minocycline. After positive data from its previously reported Phase 2b dose range trial of BPX-01 in acne, the company continues with Phase III clinical trial plans for BPX-01 for the cure of inflammatory lesions of acne.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.